Eric L. Buckland, Director, President and Chief Executive Officer at Bioptigen has lead technology development, strategic planning, and commercial operations at major global optics companies since 1985. Dr. Buckland was a key executive in Corning Incorporated's Photonics Technologies Division from 1999-2003, and was instrumental in the development of a new division formed to commercialize optical switching technologies for the all-optical network. Dr. Buckland earned his B.S summa cum laude and M.S in physics from North Carolina State University. He earned a Ph.D. in optics from the University of Rochester. He has been awarded 6 patents and has written more than 30 publications and conference presentations.
The SBIR program democratizes funding for emerging companies, providing critical financial resources to regions of the country that may not have access to the venture capital of the major metropolitan areas.In High-Quality Imaging Brings Vision to Researchers and Patients
We are very excited to receive clearance to introduce the EnFocus intrasurgical OCT system, which provides ophthalmic surgeons with highly resolved, real-time, deep and wide-field images for use during ophthalmic surgery...This product introduction builds upon Bioptigen’s 10-year history of delivering advanced OCT imaging tools to the ophthalmic healthcare community.In Leica receives FDA approval for EnFocus OCT
We are delighted to join Leica Microsystems. Together, we believe we can jointly leverage our ophthalmic imaging technologies, address broader research and clinical markets, and more efficiently complete the next steps in integrating OCT imaging capabilities into the operating room.In Leica Microsystems to Acquire OCT Company Bioptigen
We are very pleased to receive this award from the NCBiotech Center... The work advanced under this loan will bring ophthalmic surgeons a step closer to realizing the full potential of intrasurgical OCT.In Bioptigen Awarded $458,000 from North Carolina Biotechnology Center to Advance Intrasurgical OCT System Development
This advance brings surgeons one step closer to realizing the full value of intraoperative OCT...This is the first OCT system offering fully independent focus and zoom control for optimizing images from the cornea to the retina.In Bioptigen Unveils the Envisu IntraSurgical OCT System for Real-time Imaging During Ophthalmic Surgery
This advance brings surgeons one step closer to realizing the full value of intraoperative OCTIn Bioptigen Unveils the Envisu IntraSurgical OCT System for Real-time Imaging During Ophthalmic Surgery
This latest innovation from Bioptigen enables faster alignment, targeted explorations, and brilliant visualizations, while simultaneously viewing both OCT and color fundus images in real time...We expect this capability will be impactful not only for mouse and rat research, but also for handheld, dual-modality imaging of larger animals including cats, dogs, rabbits, and non-human primates," Buckland added. Bioptigen has begun producing and shipping the new multimodality systems from the company's North Carolina operations center, and will showcase the product at ARVO 2014 in Orlando, May 4-8.In Bioptigen Introduces Image-Guided SDOCT Technology to Advance Preclinical Eye Research
Single pixel slices are possible across the whole 3D image, allowing uniform sampling of data along a warped contour that ‘cuts’ through the center of features as small as a single capillary bed...This is a game‐changer as it allows dynamic exploration of flattened data, another important step towards true optical histology via SD‐OCT.In Bioptigen Introduces Dynamic 3D Tissue Flattening Software for Envisu SD-OCT Systems (See Video)
The importance of the ES100 attachment is that it provides a stabilized mounting solution for OCT in the operating room that minimizes disruptions to surgical procedures, while offering all of the flexibility and imaging performance of the Envisu C2300...The addition of a stable, microscope-mounted option enables exquisite OCT imaging of both anterior and posterior structures in the operating room when handheld imaging is not desired.In Bioptigen introduces operating microscope mount for FDA-cleared Envisu ophthalmic imaging system.
The importance of the ES100 attachment is that it provides a stabilized mounting solution for OCT in the operating room that minimizes disruptions to surgical procedures, while offering all of the flexibility and imaging performance of the Envisu C2300In Bioptigen introduces operating microscope mount for FDA-cleared Envisu ophthalmic imaging system.